PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2014 April 30.
Published in final edited form as:
PMCID: PMC4005809
NIHMSID: NIHMS569276

The Haiti research-based model of international public health collaboration: The GHESKIO Centers

Introduction

Haiti has some of the most challenging sociopolitical and economic problems in the world. The country has been affected by political instability and recurrent natural disasters (1, 2). It is also one of the countries most affected by HIV/AIDS and tuberculosis (TB) (3). Operational research has been essential to mount a successful response against these diseases.

In 1982, the Haitian Study Group on Kaposi’s Sarcoma and Opportunistic Infections (GHESKIO) was created with a mission of conducting operational research, training, and patient care for HIV/AIDS and associated infections. Thirty-one years later, Dr. Kathleen Sebelius, the US Health and Human Services Secretary, and Dr. Florence Guillaume, the Haitian Minister of Health (MOH), summarized the role played by GHESKIO in Haiti by saying: “We expect GHESKIO to develop public health models that can be scaled-up at the national level.” How did GHESKIO acquire these credentials?

Three Decades of HIV-Related Research in Haiti

In 1980, we established the Cornell Unit at the State University Hospital. With the introduction of oral rehydration solution (ORS) and other measures we were able to decrease the 40% in-hospital mortality rate for infants with acute diarrhea to less than 1% in the first year. In 1982, a national program for the control of diarrheal diseases was implemented with the Cornell Unit as the training site. The massive scale-up of this program is mainly responsible for the decrease in national infantile mortality from 144/1,000 in 1980 to 60/1,000 in 2000 (47).

In 1981, we were asked to evaluate adult patients with chronic diarrhea at the same hospital. These patients turned out to be the first AIDS cases recognized in Haiti. In 1982, the U.S. Centers for Disease Control and Prevention (CDC) listed Haitian race as a risk factor for HIV causing unparalleled prejudice to Haitians (814). In 1983, GHESKIO published a comprehensive description of the first AIDS cases in a resource-poor setting (15). The story of HIV/AIDS in Haiti has since been inseparable from that of GHESKIO.

GHESKIO demonstrated that modes of HIV transmission among Haitians were the same as those of other nationalities, prompting the CDC to remove Haitians from the so called “risk groups” for AIDS (1618). GHESKIO also showed that blood transfusions from paid donors were a major contributor to HIV transmission in Haiti, leading the MOH in 1986 to close all such blood banks and to put the Haitian Red Cross in charge of national blood banking operations (19).

Chronic persistent diarrhea and pulmonary TB are the hallmark of AIDS in Haiti. GHESKIO conducted seminal studies on the treatment and prevention of isosporiasis and cyclosporiasis (2023). They also led the first trials documenting the protective effect of primary and secondary isoniazid prophylaxis in the prevention of active TB in co-infected patients (24, 25). GHESKIO provides same-day TB diagnosis and treatment for patients with chronic cough coming for HIV testing after demonstrating that 30% of these patients had active TB (26). After documenting the role of sexually transmitted infections (STI) in enhancing HIV transmission GHESKIO developed a syndromic STI guide that led to a marked decrease in STIs (2728).

These research findings led to the development of the GHESKIO comprehensive HIV prevention and care model (29). With the availability of international funding in 2003, the MOH asked GHESKIO to expand its model nationwide. GHESKIO’s first 1,000 patients on ART had a 90% and 75% survival at one and five years, respectively, showing that resource-poor countries were capable of successful national ART scale-up (3031). GHESKIO documented comparable survival rates in infants on ART (32). In 2005, GHESKIO evaluated the optimal timing for ART initiation, and demonstrated that patients who initiated ART at the then recommended WHO guideline of CD4<200 cells/mm3 had four-fold higher mortality and twice as many incident TB versus those who started at a CD4 count of <350 cells/mm3 (33). This study prompted the WHO to revise their guideline to recommend earlier ART initiation (34).

GHESKIO has conducted many other studies as well. A 24-week program for feeding HIV-exposed infants with nutritional supplements and other support was associated with reduced risk of growth faltering (35). This intervention is now being adapted and scaled-up in other settings. GHESKIO has also evaluated the cost for implementing a national rapid test-and-treat program for syphilis and the cost of HIV treatment programs (3639). The MOH has since initiated a program to eradicate congenital syphilis. GHESKIO and the MOH conducted the first national study on the incidence of MDR-TB in Haiti, showing a rate of 3% in persons without previous TB treatment (4041). In 2008, GHESKIO was approved by the WHO Green Light Committee as one of only two MDR-TB treatment centers in Haiti, with Partners in Health (PIH).

GHESKIO has sought to achieve an impeccable record of ethical research in Haiti. They have had an experienced institutional review board (IRB) in place since 1984. In 2001, GHESKIO promoted the development of Haiti’s first National Ethics Committee (4244). In addition, GHESKIO has pioneered many interventions to improve the understanding of illiterate volunteers enrolled in research studies (4549).

Impact of the Earthquake and the Cholera Epidemic

GHESKIO’s response to public health emergencies in Haiti demonstrates its resilience and capacity to refocus rapidly on new emerging health priorities. Though GHESKIO lost many key personnel and 65% of its facilities in the earthquake, they managed to account for 94% of its patients on ART. At the same time, GHESKIO set-up an emergency field hospital in collaboration with U.S. HHS disaster medical assistance team that performed surgical procedures on over 3,000 patients. GHESKIO provided post-operative and rehabilitation services to 8,000 patients over the ensuing two years and assistance to over 7,000 internally displaced persons (5054).

In October 2010, Haiti experienced its first cholera epidemic. GHESKIO rapidly established cholera treatment centers inside the adjacent slums, trained 2,000 medical staff, and informed 250,000 persons in the community about modes of cholera prevention and treatment (55, 56). As of June 2013, over 33,000 patients were admitted to the GHESKIO cholera sites with 0.1% mortality. In collaboration with the MOH and PIH, GHESKIO introduced oral cholera vaccine (OCV) in Haiti (5760). The MOH has since launched a national OCV scale-up.

The Current Situation

Clinical Care

GHESKIO has been a major partner with the government and other organizations in combating the epidemic for over 30 years. The HIV prevalence in Haiti has decreased, from 6.3% in 1993 to 2.2% in 2012 (7). Over the past decade, ART has been expanded to 123 clinics providing treatment to 50,000 patients, with 1/3 of these covered by the GHESKIO network. Using the present WHO guideline for initiating ART, it is estimated that in 2014, Haiti will approach 100% ART coverage.

Training

As of June 2013, GHESKIO had trained over 11,000 medical personnel in integrated HIV prevention and care, including 3,500 physicians, 4,900 nurses, 1750 laboratory technicians and 1375 social workers. A diversified Community Advisory Board has sensitized over 300,000 community agents and leaders about HIV modes of transmission. Three specialized training programs have been established: Haiti’s first Master’s in Public Health Program (MPH) in 2005, the first Nurse Practitioner Program (NP) in 2009 and a specialized laboratory training course (SLT) in 2010. These programs are successful because they fulfilled the needs of expanding human resources and were developed in collaboration with local and international institutions: The MPH and NP programs with Quisqueya University and Cornell and the SLT course with the National Public Health Laboratory.

Research

GHESKIO has been a model of US-international collaboration. GHESKIO research evolved from early epidemiologic and natural history studies to the conduct of clinical trials supported by an NIH MERIT Award (1990) (6163). GHESKIO was designated an international site in the HIV Vaccine Trial Network (HVTN, 1997) and in the Adult Clinical Trial Group (ACTG, 2002), and as an independent Clinical Trials Unit (CTU) in 2006. GHESKIO’s productivity has been recognized by uninterrupted NIH support since 1983. The GHESKIO CTU has conducted seven adult therapeutic, nine HIV vaccine and four maternal-child-adolescent trials with 3,400 participants enrolled and retention rates of 98%. GHESKIO is currently conducting 17 investigator-initiated research projects independent of the CTU. To date, there have been over 130 peer-reviewed publications with seminal studies published in prestigious journals.

In 2000 GHESKIO was given the status of public utility by the Haitian government (64)

Beyond 2013

GHESKIO is presently implementing an NIH study to provide same-day HIV diagnosis and ART initiation, with the possibility to expand a test-and-treat intervention nationally. GHESKIO has also determined the most common human papillomavirus (HPV) serotypes in both HIV-infected and uninfected populations and plans to conduct a pilot project with the MOH to offer HPV vaccine to adolescents in an urban population. The increasing number of multi-drug resistant (MDR)-TB cases is a major concern and a priority. GHESKIO plans to evaluate new drugs and vaccines and is supported by its BSL-3 laboratory and a new MDR-TB hospital. Nutrition is another focus area with the construction of a Family Nutrition Unit. A 2007 editorial of the Journal of Infectious Diseases stated: “Operational research must be a cornerstone of future success (of AIDS interventions), and it is expected that the GHESKIO program will continue to help lead the way” (65).

References

1. Haiti earthquake 2010. Thomson Reuters Foundation;; http://www.trust.org/spotlight/Haiti-earthquake-2010.
2. International Human Development Indicators. Haiti Country Profile. United Nations Development Program; [Accessed May 1, 2013]. at: http://hdrstats.undp.org/en/countries/profiles/hti.html.
3. The World Bank. [Accessed May 1, 2013];Haiti Overview. at: http://www.worldbank.org/en/country/haiti/overview.
4. Pape JW, Mondestin B, Jasmin L, Kean BH, Rohde J, Johnson WD., Jr Management of diarrhea in Haiti: mortality reduction in 8,443 hospitalized children. WHO International Conference on Oral Rehydration Therapy; Washington, D.C. 1983. pp. 87–9.
5. Pape JW, Balasubramanyan R, Rohde JE. Intestinal Illness. In: Sandler RA, Jones TC, editors. Medical Care of Refuges. New York: Oxford University Press; 1988. pp. 364–3.
6. Enquête Mortalité, Morbidité et Utilisation des Services - EMMUS-IV, Rapport Préliminaire, HAÏTI 2005. Produced by l’Institut Haïtien de l’Enfance (IHE) with the collaboration of l’Institut Haïtien de Statistique et d’Informatique (IHSI).
7. Enquête Mortalité, Morbidité et Utilisation des Services - EMMUS-V, Rapport Préliminaire, HAÏTI 2012. Produced by l’Institut Haïtien de l’Enfance (IHE) with the collaboration of l’Institut Haïtien de Statistique et d’Informatique (IHSI).
8. [Accessed June 1, 2013];Morbidity and Mortality Weekly Report. 1982 31( 37):507–508. 513–514. at: http://www.cdc.gov/mmwr/preview/mmwrhtml/00001163.htm. [PubMed]
9. Moskowitz LB, Kory P, Chan JC, Haverkos HW, Conley FK, Hensley GT. Unusual causes of death in Haitians residing in Miami. High prevalence of opportunistic infections. JAMA: the journal of the American Medical Association. 1983;250:1187–91. [PubMed]
10. Jaffe HW, Bregman DJ, Selik RM. Acquired immune deficiency syndrome in the United States: the first 1,000 cases. The Journal of infectious diseases. 1983;148:339–45. [PubMed]
11. Pitchenik AE, Fischl MA, Dickinson GM, et al. Opportunistic infections and Kaposi’s sarcoma among Haitians: evidence of a new acquired immunodeficiency state. Annals of internal medicine. 1983;98:277–84. [PubMed]
12. Cohen J. Making Headway Under Hellacious Circumstances. [Accessed June 1, 2013];Science Magazine. 2006 Jul 28; at: http://www.sciencemag.org/content/313/5786/470.2.summary. [PubMed]
13. Farmer PE. AIDS and Accusation. Berkeley: University of California Press; 1992.
14. Pape JW, Liautaud B, Thomas F, Mathurin J-R, StAmand M-M, Boncy M, Pean V, Pamphile M, Laroche AC, Johnson WD., Jr Characteristics of the acquired immunodeficiency syndrome (AIDS) in Haiti. N Engl J Med. 1983;309:945–50. [PubMed]
15. Pape JW, Liautaud B, Thomas F, Mathurin J-R, St Amand M-M, Boncy M, Pean V, Pamphile M, Laroche AC, DeHovitz J, Johnson WD., Jr The acquired immunodeficiency syndrome in Haiti. Ann Int Med. 1985;103:674–8. [PubMed]
16. Pape JW, Liautaud B, Thomas F, Mathurin J-R, StAmand M-M, Boncy M, Pean V, Pamphile M, Laroche AC, Johnson WD., Jr Risk factors associated with AIDS in Haiti. Am J Med Sci. 1986;291:4–7. [PubMed]
17. Pape JW, Stanback ME, Pamphile M, Boncy M, Deschamps MM, Verdier RI, Beaulieu ME, Blattner W, Liautaud B, Johnson WD., Jr Prevalence of HIV infection and high-risk activities in Haiti. J Acquir Immune Defic Syndr. 1990;3:995–1001. [PubMed]
18. Pape JW, Johnson WD., Jr . Epidemiology of AIDS in the Caribbean. In: Piot P, Mann J, editors. Baillier’s Clinical Tropical Medicine & Communicable Diseases. Vol. 3. Bailliere Tindall Limited, Harcourt Brace Jovanovich; London: 1988. pp. 31–42.
19. Morbidity and Mortality Weekly Report 1985 May 10 Current Trends Update: Acquired Immunodeficiency Syndrome United States
20. DeHovitz JA, Pape JW, Boncy M, Johnson WD., Jr Clinical manifestations and therapy of Isospora belli infection in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1986;315:87–90. [PubMed]
21. Pape JW, Verdier R-I, Johnson WD. Treatment and prophylaxis of Isospora belli infection in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1989;320:1044–7. [PubMed]
22. Pape JW, Verdier RI, Boncy M, Boncy J, Johnson WD., Jr Cyclospora infection in adults infected with HIV. Clinical manifestations, treatment, and prophylaxis. Ann Intern Med. 1994;121:654–7. [PubMed]
23. Verdier RI, Fitzgerald DW, Johnson WD, Jr, Pape JW. Trimethoprim-sulfamethoxazole compared with ciprofloxacin for treatment and prophylaxis of Isospora belli and Cyclospora cayetanensis infection in HIV-infected patients. A randomized, controlled trial. Ann Intern Med. 2000;132:885–8. [PubMed]
24. Pape JW, Jean S, Ho J, Hafner A, Johnson WD., Jr Effect of Isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet. 1993;342:268–72. [PubMed]
25. Fitzgerald DW, Desvarieux M, Severe P, Joseph P, Johnson WD, Jr, Pape JW. Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1 infected individuals: a randomized trial. Lancet. 2000;356:1470–74. [PubMed]
26. Burgess AL, Fitzgerald DW, Severe P, Joseph P, Noel E, Rastogi N, Johnson WD, Jr, Pape JW. Integration of tuberculosis screening at an HIV voluntary counseling and testing center in Haiti. AIDS. 2001;15:1875–9. [PubMed]
27. Deschamps MM, Pape JW, Hafner A, Johnson WD., Jr Heterosexual transmission of HIV in Haiti. Ann Intern Med. 1996;125:324–30. [PubMed]
28. Mellon RL, Liautaud B, Pape JW, Johnson WD., Jr Association of HIV and STDs in Haiti: implications for blood banks and HIV vaccine trials. Journal of acquired immune deficiency syndromes and human retrovirology: official publication of the International Retrovirology Association. 1995;8:214. [PubMed]
29. Peck R, Fitzgerald DW, Liautaud B, Deschamps MM, Verdier RI, Beaulieu ME, Grand Pierre R, Joseph P, Severe P, Noel F, Wright P, Johnson WD, Jr, Pape JW. The feasibility, demand and effect of integrating primary care services with HIV voluntary counseling and testing: evaluation of a 15-year experience in Haiti, 1985–2000. J Acquir Immune Defic Syndr. 2003;33:470–5. [PubMed]
30. Severe P, Leger P, Charles M, Noel F, Bonhomme G, Bois G, George E, Kenel-Pierre S, Wright P, Gulick R, Johnson WD, Jr, Pape JW, Fitzgerald DW. Antiretroviral therapy in a thousand patients with AIDS in Haiti. New Eng J Med. 2005;353:2325–2334. [PubMed]
31. Leger P, Macarthur Charles, Severe P, Riviere C, Anne Beauharnais Carole, Koenig S, Miller E, Johnson WD, Jr, Pape JW, Fitzgerald DW. Five-year Survival of Patients with AIDS Receiving Antiretroviral Therapy in Haiti. N Engl J Med. 2009;361:828–829. [PMC free article] [PubMed]
32. George E, Noel F, Bois G, Cassagnol R, Estavien L, Rouzier P, Verdier R, Johnson WD, Jr, Pape JW, Fitzgerald DW, Wright P. Antiretroviral therapy for HIV-infected children in Haiti. J Infect Dis. 2007;195:1411–8. [PubMed]
33. Severe P, Jean Juste MA, Ambroise A, Eliacin L, Marchand C, Apollon S, Edwards A, Bang H, Nicotera J, Godfrey C, Gulick R, Johson W, Pape J, Fitzgerald D. Early versus Standard Antiretroviral Therapy for HIV-Infected Adults in Haiti. N Engl J Med. 2010;363:257–265. [PMC free article] [PubMed]
34. WHO change in guidelines World Health Organization. [Accessed May 1, 2013];Rapid Advice: antiretroviral therapy for HIV infection in adults and adolescents. 2009 at: http://www.who.int/hiv/pub/arv/advice/en/index.html.
35. Heidkamp RA, Stoltzfus RJ, Fitzgerald DW, Pape JW. Growth in late infancy among HIV-exposed children in urban Haiti is associated with participation in a clinic-based infant feeding support intervention. J Nutr. 2012 Apr;142(4):774–80. [PubMed]
36. Schackman BR, Neukermans CP, Fontain SN, Nolte C, Joseph P, Pape JW, Fitzgerald DW. Cost-Effectiveness of Rapid Syphilis Screening in Prenatal HIV Testing Programs in Haiti. Plos Medicine. 2007;4:e183. [PMC free article] [PubMed]
37. Koenig SP, Riviere C, Leger P, Atwoods S, Fitzgerald DW, Pape JW, Schackman Br. The cost of antiretroviral therapy in Haiti. Cost Eff Resour Alloc. 2008;6:3. [PMC free article] [PubMed]
38. Koenig S, Schackman B, Riviere C, Leger P, Charles M, Severe P, Lastimoso C, Colucci N, Pape JW, Fitzgerald D. Clinical Impact and Cost of Monitoring for Asymptomatic Laboratory Abnormalities among Patients Receiving Antiretroviral Therapy in a Resource-Poor Setting. Clin Infect Dis. 2010;51:600–610. [PMC free article] [PubMed]
39. Koenig SP, Bang H, Severe P, Jean Juste MA, Ambroise A, Edwards A, Hippolyte J, Fitzgerald DW, McGreevy J, Riviere C, Marcelin S, Secours R, Johnson WD, Pape JW, Schackman BR. Cost-Effectiveness of Early Versus Standard Antiretroviral Therapy in HIV-Infected Adults in Haiti. Plos Medicine. 2011;8:9. [PMC free article] [PubMed]
40. Joseph P, Sévère P, Ferdinand S, Goh KS, Sola C, Haas D, Johnson WD, Rastogi N, Pape JW, Fitzgerald DW. Multi-drug resistant tuberculosis at an HIV testing Center in Haiti. AIDS. 2006;20:415–418. [PubMed]
41. Ocheretina O, Morose W, Gauthier M, Joseph P, D’Meza R, Escuyer V, Rastogi N, Vernet G, Pape JW, Fitzgerald DW. Multidrug-resistant tuberculosis in Port-au-Prince, Haiti. Pan American Journal of Public Health. 2012 Mar;31(3):221–4. [PMC free article] [PubMed]
42. Pape JW. Institution Review Boards: Consideration in Developing Countries. Emerg Infect Dis. 2001;7(3 Supple):547. [PMC free article] [PubMed]
43. Fitzgerald DW, Wasunna A, Pape JW. Ten questions institutional review boards should ask when reviewing international clinical research protocols. IRB. 2003;25:14–8. [PubMed]
44. Fitzgerald DW, Wasunna A, Crigger B, Pape JW. Building Ethics Capacity in Haiti. Developing World Bioethics. 2003;3:3–9.
45. Fitzgerald DW, Marotte C, Verdier RI, Johnson WD, Jr, Pape JW. Comprehension during informed consent in a less-developed country. Lancet. 2002;360:1301–2. [PubMed]
46. Joseph P, Schackman B, Horowitz R, Nérette S, Verdier RI, Dorsainvil D, Theodore H, Ascencio M, Henrys K, Wright P, Johnson WD, Pape JW, Fitzgerald DW. The use of an educational video during informed consent in an HIV clinical trial in Haiti. JAIDS. 2006;42:588–591. [PubMed]
47. Fitzgerald DW, Maxi A, Marcelin A, Johnson WD, Jr, Pape JW. Notification of positive HIV test results in Haiti: can we better intervene at this critical crossroads in the life of HIV-infected patients in a resource-poor country? AIDS Patient Care STDs. 2004;18:658–64. [PubMed]
48. Horwitz RH, Roberts LW, Seal DW, Joseph P, Maschke KJ, Verdier RI, Nerette S, Pape JW, Fitzgerald DW. Assessing whether consent for a clinical trial is voluntary. Ann Intern Med. 2013 Feb 5;158(3):222–4. [PMC free article] [PubMed]
49. Fitzgerald DW, Pape JW, Wasserheit JN, Counts GW, Corey L. Provision of treatment in HIV-1 vaccine trials in developing countries. Lancet. 2003;20:993–4. [PubMed]
50. Pape JW, Johnson WD, Fitzgerald DW. The Earthquake in Haiti — Dispatch from Port-au-Prince. N Engl J Med. 2010;362:575–577. [PubMed]
51. Pape J. Global health. Haiti’s quake shifts clinic’s focus from AIDS to AID. Science. 2010;327(5965):509. [PubMed]
52. Hopmeier M, Pape JW, Paulison D, Carmona R, Davis T, Peleg K, Shennar G, Conway-Welch C, Vermund S, Kellerma A, Nicotera J. Reflections on the initial multinational response to the earthquake in Haiti. Popul Health Manag. 2010;13:3. [PubMed]
53. Pape JW, Deschamps MM, Ford H, Joseph P, Johnson WD, Fitzgerald DW. The GHESKIO Refugee Camp after the Earthquake in Haiti — Dispatch 2 from Port-au-Prince. N Engl J Med. 2010;362:e27. [PubMed]
54. Pape JW, Rouzier V, Ford H, Joseph P, Johnson WD, Fitzgerald DW. The GHESKIO Field Hospital and Clinics after the Earthquake in Haiti – Dispatch 3 from Port-au-Prince. N Engl J Med. 2010;362:e34. [PubMed]
55. Farmer P, Almazor CP, Bahnsen ET, et al. Meeting cholera’s challenge to Haiti and the world: A joint statement on cholera prevention and care. Plos Neg Trop Dis. 2011;5:e1145. [PMC free article] [PubMed]
56. May JP, Joseph P, Pape JW, Binswnager IA. Health care for prisoners in Haiti. Ann Intern Med. 2010;153:407–10. [PubMed]
57. Hinman A, Farmer P, Pape JW, Ivers L, Leandre F, Wiegel J, Rosenberg M. Cholera Vaccination in Haiti. Harvard International Review. 2011:51–57.
58. Ivers L, Pape JW, Farmer P. Oral cholera vaccine and integrated cholera control in Haiti. Lancet. 2012 Jun 2;379(9831):2026–8. [PubMed]
59. Rouzier V, Severe K, Jean Juste MA, et al. Providing oral cholera vaccine in an urban slum in Haiti accepted ASTMH
60. Valcin Cl, Severe K, Riche CT, et al. Predictors of disease severity in patients admitted to a cholera treatment center in urban Haiti accepted ASTMH [PMC free article] [PubMed]
61. Deschamps MM, Fitzgerald DW, Pape JW, Johnson WD., Jr HIV infection in Haiti: natural history and disease progression. AIDS. 2000;14:2515–21. [PubMed]
62. Deschamps MM, Pape JW, Desvarieux M, Williams-Russo P, Madhavan S, Ho JL, Johnson WD., Jr A prospective study of HIV seropositive asymptomatic women of childbearing age in a developing country. J AIDS. 1993;6:446–51. [PubMed]
63. Jean SS, Pape JW, Verdier RI. The natural history of human immunodeficiency virus 1 infection in Haitian infants. Ped Infect Dis J. 1999;18:58–63. [PubMed]
64. Le Moniteur Jounral Officiel de la Republique d’Haiti. 71. Port-au-Prince; Haiti: Sep, 2000.
65. Adams LV, Columbo P. The Time to treat children is now. Editorial Comentary. JID. 2007;195:1396–1398. [PubMed]